A compendium of critical appraisals in Intensive Care Medicine research and related specialties
Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis Ware. JAMA 2024. doi:10.1001/jama.2024.8772 Clinical Question In critically ill adult patients with sepsis does the administration of acetaminophen compared to placebo increase the number of days alive and free of organ support to day 28? Background Acetaminophen is a potent and specific haemoprotein reductant that can […]
Continue reading »
In critically ill adult patients with presumed sepsis, does the administration of β-lactam antibiotics via a continuous infusion compared to an intermittent infusion reduce 90-day mortality?
Continue reading »
In acutely ill adults (ED / ICU) does the administration of cefipime or piperacillin-tazobactam (pip-taz) result in an increased incidence of AKI or death by day 14?
Continue reading »
Landiolol and Organ Failure in Patients With Septic Shock Whitehouse. JAMA Published online October 25, 2023. doi:10.1001/jama.2023.20134 Clinical Question In patients with tachycardia and septic shock who are treated with high dose norepinephrine does the use of β-blockade for up to 14 days reduce organ failure compared to standard care? Background Many view the use of β-blockade as contentious in […]
Continue reading »
In patients with sepsis-induced hypotension does a restrictive fluid strategy (with early vasopressor usage) compared to a liberal fluid strategy result in lower mortality before discharge by day 90?
Continue reading »
In adult patients with sepsis receiving vasopressor therapy, does a high dose of vitamin C in comparison to placebo, reduce the risk of death or persistent organ dysfunction at 28 days?
Continue reading »
In septic adults at high risk for invasive candida infection (ICI) does the use (1,3)-β-D-glucan (BDG) guided antifungal strategy, compared with standard treatment, reduce 28-day mortality compared to standard care?
Continue reading »
In adult patients in ICU with septic shock, does a restrictive approach to fluid therapy compared to a standard care result in fewer deaths at day 90?
Continue reading »
In hospitalised patients with severe acute respiratory syndrome due to coronavirus 2 (SAR-CoV-2), does tocilizumab compared with placebo, reduce intubation rates or mortality?
Continue reading »
In patients admitted to hospital with COVID-19, does Lopinavir-ritonavir therapy (Kaletra) compared to usual care, reduce 28-day mortality?
Continue reading »